{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:58:48Z","timestamp":1770577128069,"version":"3.49.0"},"reference-count":27,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":327,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myocarditis is a potentially fatal cardiac disease marked by inflammation of the heart muscle. With a noted black-box warning, rates of clozapine-induced myocarditis are reportedly as high as 3%. Since the first case of clozapine-induced myocarditis was documented in 1994, more than 250 cases have been described in literature with an approximate 33% case-fatality rate. We report 2 cases of patients with primary psychotic disorders treated with clozapine, who developed signs and symptoms of myocarditis. The first was a 35-year-old white male patient with a primary diagnosis of schizoaffective disorder (bipolar type) who was initiated on clozapine after nonresponse to several therapies. On day 26, the patient was admitted to the emergency department for chest pain presenting with eosinophilia and notable elevations in several biomarkers, including troponin and C-reactive protein. The second patient was a 45-year-old black male who was initiated on clozapine for treatment-resistant schizophrenia. On day 13, the patient reported cardiac-related concerns (tachycardia) and flu-like symptoms resulting in hospitalization. Similarly, this patient demonstrated elevated biomarkers (troponin and creatine kinase). Both patients experienced resolution of symptoms after discontinuation of clozapine. Clozapine was not rechallenged for either patient. Review of literature further elucidates the relationship between clozapine and myocarditis, including potential risk factors, pathophysiology, and symptom presentation. Due to the potentially fatal nature of this condition, clinical vigilance and awareness is warranted upon initiation of clozapine through monitoring of symptoms along with cardiac and inflammatory biomarkers as indicated.<\/jats:p>","DOI":"10.9740\/mhc.2018.11.303","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T18:09:22Z","timestamp":1541095762000},"page":"303-308","source":"Crossref","is-referenced-by-count":12,"title":["Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition"],"prefix":"10.9740","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-0264","authenticated-orcid":false,"given":"Bryan K.","family":"Sackey","sequence":"first","affiliation":[{"name":"(Corresponding author) Mental Health Clinical Pharmacy Specialist, Pharmacy Department, South Texas Veterans Healthcare System, San Antonio, Texas; Adjoint Assistant Professor, Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, bryan.sackey@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-4028","authenticated-orcid":false,"given":"Troy A.","family":"Moore","sequence":"first","affiliation":[{"name":"Mental Health Clinical Pharmacy Specialist, Pharmacy Department, South Texas Veterans Healthcare System, San Antonio, Texas; Director, American Society of Health-System Pharmacists\u2013Accredited Postgraduate Year 2 Psychiatric Pharmacy Residency Program; Assistant Professor, Division of Community Recovery, Research and Training, Department of Psychiatry, University of Texas Health Science Center at"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-4051","authenticated-orcid":false,"given":"Nicole L.","family":"Cupples","sequence":"first","affiliation":[{"name":"Mental Health Clinical Pharmacy Specialist, Pharmacy Department, South Texas Veterans Healthcare System, San Antonio, Texas; Adjoint Assistant Professor, Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-8554","authenticated-orcid":false,"given":"Cynthia A.","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Associate Chief, Clinical Pharmacy Programs and Mental Health Clinical Pharmacy Specialist, Pharmacy Department, South Texas Veterans Healthcare System, San Antonio, Texas; Assistant Clinical Professor, Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"33","key":"2020060307285282000_i2168-9709-8-6-303-b01","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"European Hear J"},{"issue":"9","key":"2020060307285282000_i2168-9709-8-6-303-b02","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","article-title":"Update on myocarditis","volume":"59","author":"Kindermann","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2020060307285282000_i2168-9709-8-6-303-b03","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-200108000-00005","article-title":"Myocarditis related to clozapine treatment","volume":"21","author":"H\u00e4gg","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"28","key":"2020060307285282000_i2168-9709-8-6-303-b04","first-page":"4151","article-title":"[Allergic myocarditis in clozapine treatment]","volume":"156","author":"Jensen","year":"1994","journal-title":"Ugeskr Laeger"},{"issue":"9193","key":"2020060307285282000_i2168-9709-8-6-303-b05","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"2020060307285282000_i2168-9709-8-6-303-b06","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine use in the United States","volume":"345","author":"Grenade","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2020060307285282000_i2168-9709-8-6-303-b07","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488612800492681","article-title":"Update on the adverse effects of clozapine: focus on myocarditis","volume":"7","author":"De Berardis","year":"2012","journal-title":"Curr Drug Saf"},{"issue":"3","key":"2020060307285282000_i2168-9709-8-6-303-b08","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3371\/1935-1232.10.3.163","article-title":"Guide to the management of clozapine-related tolerability and safety concerns","volume":"10","author":"Citrome","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"9206","key":"2020060307285282000_i2168-9709-8-6-303-b09","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0140-6736(00)00035-0","article-title":"Clozapine and sudden death","volume":"355","author":"Devarajan","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2020060307285282000_i2168-9709-8-6-303-b10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf"},{"issue":"2","key":"2020060307285282000_i2168-9709-8-6-303-b11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1-3","key":"2020060307285282000_i2168-9709-8-6-303-b12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2016.04.016","article-title":"Clozapine-induced myocarditis","volume":"174","author":"Swart","year":"2016","journal-title":"Schizophr Res"},{"key":"2020060307285282000_i2168-9709-8-6-303-b13","doi-asserted-by":"publisher","first-page":"513108","DOI":"10.1155\/2014\/513108","article-title":"Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition?","volume":"2014","author":"Munshi","year":"2014","journal-title":"Case Rep Psychiatry"},{"issue":"6","key":"2020060307285282000_i2168-9709-8-6-303-b14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2020060307285282000_i2168-9709-8-6-303-b15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1574886309666140428115040","article-title":"Clozapine safety, 40 years later","volume":"9","author":"Raja","year":"2014","journal-title":"Curr Drug Saf"},{"issue":"4","key":"2020060307285282000_i2168-9709-8-6-303-b16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","article-title":"Clozapine-induced cardiotoxicity: a clinical update","volume":"190","author":"Layland","year":"2009","journal-title":"Med J Aust"},{"key":"2020060307285282000_i2168-9709-8-6-303-b17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijcard.2017.03.013","article-title":"Clozapine and incidence of myocarditis and sudden death \u2013 long term Australian experience","volume":"238","author":"Khan","year":"2017","journal-title":"Int J Cardiol"},{"key":"2020060307285282000_i2168-9709-8-6-303-b18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2017.12.102","article-title":"A systematic review of clozapine-induced myocarditis","volume":"259","author":"Bellissima","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"2020060307285282000_i2168-9709-8-6-303-b19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4088\/JCP.11l07467","article-title":"Observations from 8 cases of clozapine rechallenge after development of myocarditis","volume":"73","author":"Ronaldson","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2020060307285282000_i2168-9709-8-6-303-b20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0091217415621269","article-title":"Clozapine-induced myocarditis may be associated with rapid titration","volume":"51","author":"Chopra","year":"2016","journal-title":"Int J Psychiatry Med"},{"issue":"2-3","key":"2020060307285282000_i2168-9709-8-6-303-b21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","article-title":"Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study","volume":"141","author":"Ronaldson","year":"2012","journal-title":"Schizophrenia Res"},{"issue":"2","key":"2020060307285282000_i2168-9709-8-6-303-b22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/1039856215604480","article-title":"and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia","volume":"24","author":"Youssef","year":"2016","journal-title":"Australas Psychiatry"},{"issue":"5","key":"2020060307285282000_i2168-9709-8-6-303-b23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/0004867414566871","article-title":"Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis","volume":"49","author":"Ronaldson","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"2020060307285282000_i2168-9709-8-6-303-b24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"2020060307285282000_i2168-9709-8-6-303-b25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1440-1614.2001.0884a.x","article-title":"Clozapine rechallenge after myocarditis","volume":"35","author":"Reid","year":"2001","journal-title":"Aust N Z J Psychiatry"},{"issue":"11-2","key":"2020060307285282000_i2168-9709-8-6-303-b26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/j.1440-1614.2004.01481.x","article-title":"Clozapine-related myocarditis and cardiomyopathy in an Australian Metropolitan Psychiatric Service","volume":"38","author":"Reinders","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"issue":"2-3","key":"2020060307285282000_i2168-9709-8-6-303-b27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","article-title":"When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature","volume":"134","author":"Manu","year":"2012","journal-title":"Schizophr Res"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/6\/303\/2096460\/mhc_2018_11_303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/6\/303\/2096460\/mhc_2018_11_303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:48Z","timestamp":1731687768000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/8\/6\/article-p303.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2018.11.303","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}